Home
      Contact Us | Site Map | SEARCH
 
About HDN
About RHOPHYLAC
The Rhophylac Promise
Professional Resources
Clinical Resources
Meetings
FAQ
Ordering/Reimbursement
Patient Education
Request More Information
Important Saftey Information
Prescribing Information


Professional Resources

CSL Behring offers a variety of helpful resources for healthcare professionals. Click on the links below for details or to access resources.

Informational Video

View this interactive video for essential information on CSL Behring, HDN, and Rhophylac®.

Clinical Resources

Request any or all of these journal reprints about HDN and Rhophylac®, and CSL Behring will send you the articles via USPS mail.

Needle Guide

This step-by-step, illustrated guide is designed to help you protect your patients by explaining how to safely and easily administer Rhophylac®. Also contains information on the SAFSITE Needle-free IV System.

Meetings and Teleconferences

Learn more about Rhophylac® and recent advances in prophylaxis treatment by attending a meeting or teleconference, which feature discussions by Key Opinion Leaders.

FAQs

Get answers to frequently asked questions about Rhophylac®.


© CSL Behring 2008. The product information on this site is intended for US residents only.

Important Safety Information

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isommunization, Rhophylac® can be administered IM or IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Please see full prescribing information.